Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Madalena Tarsounas' group have recently published two new papers in EMBO Molecular Medicine and Nature Communications.

Tarsounas group
The Tarsounas group, Department of Oncology

In Tacconi et al . they discovered that chlorambucil, an alkylating agent in clinical use for the treatment of leukemia, has a high therapeutic potential against BRCA1/2-mutated tumours. Importantly, while being equally effective as cisplatin against this tumour subset, chlorambucil showed significantly lower overall toxicity.

Find the original publication here:

https://www.embopress.org/lookup/doi/10.15252/emmm.201809982

 

In Reisländer et al. they demonstrated that loss of BRCA2 leads to activation of the cGAS-STING pathway which results in a cell-intrinsic type I interferon response. Importantly, this innate immune response in BRCA2-deficient cells is potentiated by treatment with PARP inhibitors.

Find the original publication here:

https://www.nature.com/articles/s41467-019-11048-5